{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:05:35Z","timestamp":1784304335921,"version":"3.55.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jacl.2015.07.006","type":"journal-article","created":{"date-parts":[[2015,7,22]],"date-time":"2015-07-22T02:34:54Z","timestamp":1437532494000},"page":"S57-S66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"S","title":["Lipoprotein(a): Its relevance to the pediatric population"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0655-2052","authenticated-orcid":false,"given":"Catherine J.","family":"McNeal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2015.07.006_bib1","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","article-title":"Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants","volume":"55","author":"Erqou","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.07.006_bib2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.07.006_bib3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/joim.12187","article-title":"Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease","volume":"276","author":"Hopewell","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2015.07.006_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2015.07.006_bib5","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacl.2015.07.006_bib6","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1093\/eurheartj\/eht053","article-title":"When should we measure lipoprotein (a)?","volume":"34","author":"Kostner","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.07.006_bib7","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.07.006_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.7326\/0003-4819-151-7-200910060-00010","article-title":"Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force","volume":"151","author":"Helfand","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2015.07.006_bib9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.07.006_bib10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11886-999-0067-z","article-title":"Lipoprotein(a) and coronary heart disease risk","volume":"1","author":"Marcovina","year":"1999","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacl.2015.07.006_bib11","first-page":"d546","article-title":"Apolipoprotein(a): structure and biology","volume":"6","author":"Scanu","year":"2001","journal-title":"Front Biosci"},{"key":"10.1016\/j.jacl.2015.07.006_bib12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jacl.2010.07.002","article-title":"Management of Lp(a)","volume":"4","author":"Brown","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.07.006_bib13","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1172\/JCI119055","article-title":"Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine","volume":"98","author":"Mooser","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2015.07.006_bib14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/MOL.0b013e3283598d81","article-title":"Emerging therapeutic agents to lower lipoprotein (a) levels","volume":"23","author":"Kolski","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2015.07.006_bib15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein [a] gene accounts for greater than 90% of the variation in plasma lipoprotein[a] concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2015.07.006_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2015.07.006_bib17","doi-asserted-by":"crossref","first-page":"24004","DOI":"10.1074\/jbc.270.41.24004","article-title":"The Recurring evolution of lipoprotein(a) insights from cloning of hedgehog apolipoprotein(a)","volume":"270","author":"Lawn","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2015.07.006_bib18","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jacc.2009.12.048","article-title":"The mysteries of lipoprotein(a) and cardiovascular disease revisited","volume":"55","author":"Kiechl","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.07.006_bib19","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.mayocp.2013.09.003","article-title":"Lipoprotein(a), cardiovascular disease, and contemporary management","volume":"88","author":"Jacobson","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2015.07.006_bib20","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.ATV.20.12.2619","article-title":"High levels of Lp(a) with a small apo(a)isoform are associated with coronary artery disease in African American and white men","volume":"20","author":"Paultre","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2015.07.006_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.07.006_bib22","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/01.ATV.0000144010.55563.63","article-title":"Lipoprotein(a): an elusive cardiovascular risk factor","volume":"24","author":"Berglund","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2015.07.006_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/MOL.0000000000000070","article-title":"Lipoprotein(a) metabolism","volume":"25","author":"Lamon-Fava","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2015.07.006_bib24","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11883-013-0360-6","article-title":"Update on lipoprotein(a) as a cardiovascular risk factor and mediator","volume":"15","author":"Boffa","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2015.07.006_bib25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.atherosclerosis.2012.09.031","article-title":"In\u00a0vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a)","volume":"225","author":"Frischmann","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.07.006_bib26","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0038-1653797","article-title":"Interaction of Lp(a) with plasminogen binding sites on cells","volume":"73","author":"les","year":"1995","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.jacl.2015.07.006_bib27","article-title":"What drives \u201cfibrinolysis\u201d?","volume":"35","author":"Medcalf","year":"2015","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jacl.2015.07.006_bib28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.thromres.2014.01.024","article-title":"Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties","volume":"133","author":"Rowland","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacl.2015.07.006_bib29","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0009-3084(94)90159-7","article-title":"Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator","volume":"67-68","author":"Angeles-Cano","year":"1994","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.jacl.2015.07.006_bib30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2362.1996.156288.x","article-title":"The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin","volume":"26","author":"Hervio","year":"1996","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacl.2015.07.006_bib31","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/S0022-2275(20)31990-8","article-title":"Characterization of the basis of lipoprotein [a] lysine-binding heterogeneity","volume":"41","author":"Xia","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.07.006_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0005-2760(96)00055-0","article-title":"Oxidation of lipoprotein(a) and low density lipoprotein containing density gradient ultracentrifugation fractions","volume":"1303","author":"Kleinvald","year":"1996","journal-title":"Biochemica Biophys Acta"},{"key":"10.1016\/j.jacl.2015.07.006_bib33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp (a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.07.006_bib34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jth.12056","article-title":"Lipoprotein(a), polymorphisms in the LPA gene, and incident venous thromboembolism among 21483 women","volume":"11","author":"Danik","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.jacl.2015.07.006_bib35","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2015.07.006_bib36","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/jth.12699","article-title":"No impact of endogenous prothrombotic conditions on the risk of central venous line-related thrombotic events in children: results of the KIDCAT study (KIDs with Catheter Associated Thrombosis)","volume":"12","author":"Thom","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacl.2015.07.006_bib37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacl.2014.08.003","article-title":"Lipoprotein(a) mass: a massively misunderstood metric","volume":"8","author":"McConnell","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.07.006_bib38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2015.07.006_bib39","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1194\/jlr.M012526","article-title":"Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study","volume":"52","author":"Lamon-Fava","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.07.006_bib40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1476-511X-3-29","article-title":"Correlates of serum lipoprotein (A) in children and adolescents in the United States. The third National Health Nutrition and Examination Survey (NHANES-III)","volume":"3","author":"Obisesan","year":"2004","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2015.07.006_bib41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cca.2014.10.013","article-title":"Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis","volume":"439","author":"Guadagno","year":"2015","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacl.2015.07.006_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0009-8981(98)00186-7","article-title":"Quantitative determination of cholesterol in lipoprotein fractions by electrophoresis","volume":"282","author":"Contois","year":"1999","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacl.2015.07.006_bib43","first-page":"13","article-title":"Analytical performance of the Genzyme LipoPro Lp(a) kit for plasma lipoprotein(a)-cholesterol assay","volume":"57","author":"Gaw","year":"2000","journal-title":"Br J Biomed Sci"},{"key":"10.1016\/j.jacl.2015.07.006_bib44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacl.2012.01.004","article-title":"Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups","volume":"6","author":"Konerman","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2015.07.006_bib45","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2015.07.006_bib46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2014.01.049","article-title":"Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk","volume":"234","author":"Langsted","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.07.006_bib47","series-title":"Lipoprotein(a)","first-page":"151","article-title":"Incidence of Lp(a) among populations","author":"Dahlen","year":"1990"},{"key":"10.1016\/j.jacl.2015.07.006_bib48","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/clinchem\/40.4.571","article-title":"Effect of serum lipoprotein(a) on estimation of low-density lipoprotein cholesterol by the Friedewald formula","volume":"40","author":"Li","year":"1994","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2015.07.006_bib49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0021-9150(02)00034-5","article-title":"Does correction of the Friedewald formula using lipoprotein(a) change our estimation of ischemic heart disease risk? The Quebec Cardiovascular Study","volume":"163","author":"Cantin","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.07.006_bib50","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.clinbiochem.2014.04.023","article-title":"Marked effects of extreme levels of lipoprotein(a) on estimation of low-density lipoprotein cholesterol","volume":"47","author":"Saeedi","year":"2014","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jacl.2015.07.006_bib51","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2015.07.006_bib52","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11936-010-0077-6","article-title":"Do we know when and how to lower lipoprotein(a)?","volume":"12","author":"Joshi","year":"2010","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.jacl.2015.07.006_bib53","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.07.006_bib54","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.07.006_bib55","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/clinchem\/48.9.1454","article-title":"Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases","volume":"48","author":"Akaike","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2015.07.006_bib56","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.07.006_bib57","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.05.003","article-title":"Effect of aspirin on lipoprotein(a) in patients with ischemic stroke","volume":"16","author":"Ranga","year":"2007","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jacl.2015.07.006_bib58","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.2174\/1381612811209023019","article-title":"Antiplatelet therapy in children: why so different from adults'?","volume":"18","author":"Bassareo","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacl.2015.07.006_bib59","first-page":"1472","article-title":"FPIN's Clinical Inquiries. Aspirin use in children for fever or viral syndromes","volume":"80","author":"Beutler","year":"2009","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jacl.2015.07.006_bib60","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1373\/clinchem.2014.225946","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia","volume":"60","author":"Awan","year":"2014","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2015.07.006_bib61","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2174\/138161211795428777","article-title":"Lipoprotein(a): medical treatment options for an elusive molecule","volume":"17","author":"Parhofer","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacl.2015.07.006_bib62","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2015.07.006_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2710.2011.01244.x","article-title":"Optimal therapy for reduction of lipoprotein(a)","volume":"37","author":"Lippi","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jacl.2015.07.006_bib64","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/ijo.2009.144","article-title":"Decrease of Lp(a) during weight reduction in obese children is modified by the apo(a) kringle-IV copy number variation","volume":"33","author":"Brandst\u00e4tter","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jacl.2015.07.006_bib65","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1824-7288-40-42","article-title":"Plant sterols-enriched diet decreases small, dense LDL-cholesterol levels in children with hypercholesterolemia: a prospective study","volume":"40","author":"Garoufi","year":"2014","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.jacl.2015.07.006_bib66","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11745-013-3834-y","article-title":"The effect of an energy restricted low glycemic index diet on blood lipids, apolipoproteins and lipoprotein(a) among adolescent girls with excess weight: a randomized clinical trial","volume":"48","author":"Rouhani","year":"2013","journal-title":"Lipids"},{"key":"10.1016\/j.jacl.2015.07.006_bib67","first-page":"711","article-title":"The effects of weight loss and apolipoprotein E polymorphism on serum lipids, apolipoproteins A-I and B, and lipoprotein(a)","volume":"17","author":"Muls","year":"1993","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.jacl.2015.07.006_bib68","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1463-1326.2002.00181.x","article-title":"Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity","volume":"4","author":"Gokcel","year":"2002","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacl.2015.07.006_bib69","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000023468","article-title":"Lipoprotein(a) levels in formerly small-for-gestational-age children","volume":"52","author":"Pulzer","year":"1999","journal-title":"Horm Res"},{"key":"10.1016\/j.jacl.2015.07.006_bib70","first-page":"351","article-title":"Lipoprotein heterogeneity at birth: influence of gestational age and race on lipoprotein subclasses and Lp (a) lipoprotein","volume":"14","author":"Kwiterovich","year":"2004","journal-title":"Ethn Dis"},{"key":"10.1016\/j.jacl.2015.07.006_bib71","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1542\/peds.89.3.401","article-title":"Early expression of the apolipoprotein (a) gene: relationships between infants' and their parents' serum apolipoprotein (a) levels","volume":"89","author":"Wang","year":"1992","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacl.2015.07.006_bib72","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0021-9150(92)90271-H","article-title":"Lipoprotein(a) at birth, in blacks and whites","volume":"92","author":"Rifai","year":"1992","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.07.006_bib73","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.CIR.84.1.160","article-title":"Racial (black-white) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study","volume":"84","author":"Srinivasan","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.07.006_bib74","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db13-1144","article-title":"The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?","volume":"63","author":"Ye","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.jacl.2015.07.006_bib75","first-page":"109","article-title":"Lipoprotein(a) in children and adolescence","volume":"1","author":"Wang","year":"2003","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.jacl.2015.07.006_bib76","first-page":"37","article-title":"Relationship between lipoprotein(a) and thyroid hormones in hypothyroid patients","volume":"8","author":"Kaliaperumal","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.jacl.2015.07.006_bib77","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1161\/STROKEAHA.108.189696","article-title":"Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young","volume":"39","author":"Roach","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.jacl.2015.07.006_bib78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ijs.12136","article-title":"Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke","volume":"9","author":"Sultan","year":"2014","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jacl.2015.07.006_bib79","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.109.913673","article-title":"Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies","volume":"121","author":"Kenet","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.07.006_bib80","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3324\/haematol.2012.073833","article-title":"Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children","volume":"98","author":"Goldenberg","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jacl.2015.07.006_bib81","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1161\/STROKEAHA.106.480657","article-title":"Lipoprotein (a) and stroke: a meta-analysis of observational studies","volume":"38","author":"Smolders","year":"2007","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.jacl.2015.07.006_bib82","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.contraception.2012.09.015","article-title":"Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users","volume":"87","author":"Sidney","year":"2013","journal-title":"Contraception"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415003074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415003074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T18:41:48Z","timestamp":1652899308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287415003074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1933287415003074"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2015.07.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a): Its relevance to the pediatric population","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2015.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}